NeopharmCO
네오팜 · 092730
Materials Chemicals · KOSDAQ
Market cap US$199.8M (₩275.7B)
Overview
NeopharmCO makes skincare and body-care products designed for sensitive or compromised skin, sold under several distinct brands including Atopalm, Real Barrier, Dermavy, TL's, and Zeroid.
Its products are aimed at consumers seeking gentle, dermatologist-oriented skincare, ranging from everyday moisturizers to medical-grade skin treatments. The company is listed on KOSDAQ, South Korea's tech and small-cap exchange, and its entire product portfolio is built around a proprietary formulation technology that mimics the natural lipid structure of healthy skin, rather than relying on individual active ingredients.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$70.4M
- FY2024US$86.2M
- FY2025US$95.8M
Operating profit
- FY2023US$18.3M
- FY2024US$17.9M
- FY2025US$20.9M
Net income
- FY2023US$16.8M
- FY2024US$16.7M
- FY2025US$20.2M
Key ratios (FY2025)
Why it matters
Its flagship brand Atopalm has held the top position in South Korea's sensitive skincare category in the K-BPI brand-power survey for over nineteen consecutive years.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?